Low-Grade Serous Ovarian Cancer Research Catalogue
We know that good information can be difficult to find with low-grade serous ovarian cancer. We have created this research repository to help people searching for specific information about the cancer. It lists most of the research currently available in the low-grade serous carcinoma field.
We have grouped research papers alphabetically by the type of research. “Significant studies” is a list of papers that we think are of particular relevance to women with this disease.
It is important to note the papers listed below were written for scientists and doctors, not patients. We strongly recommend you read our section on learning more about research and how to interpret it first. You may like to send an article to a trusted doctor or nurse, and ask them for help in interpreting the information. We also encourage you to discuss any conclusions you make from research with your cancer specialists – they will be able to add additional context which can be helpful to interpreting whether a study’s findings might relate to you.
Always remember that research only tells us what has happened in the past to a group of people (often the “average” person). Each and every patient with this disease is a unique individual – there is no guarantee that there was someone exactly like you in the research study.
Research conclusions can also change with time as further research studies and information become available. An example of this is the question – what proportion of ovarian cancer is low-grade serous cancer? These studies usually use very large national databases to draw conclusions. Older research studies figures differ to newer research study figures. This is not thought to be because the amount of women with low-grade serous has changed – but instead because doctors are getting better at making the correct diagnosis and so the quality of data in these databases is improving over time.
How to access research
Not all the papers listed below have the full research paper available.
Members of the Low-Grade Serous Peer Support Group (open to any woman with low-grade serous carcinoma) and the support group for carers/family/friends of low-grade serous women can access the articles by going to “Files” and selecting “The Research Library”. On mobile devices “Files” is located under “… More”/”View Group Info”.
Clinical Guidelines
- NCCN Ovarian Cancer Guidelines for Clinicians 2022 (includes LGSOC update)
- NCCN Ovarian Cancer Guidelines for Patients 2017 (includes LGSOC section)
Significant Studies
- Activity of bevacizumab-containing regimens in recurrent low-grade serous ovarian or peritoneal cancer: A single institution experience
- Contemporary primary treatment of women with stage II-IV low-grade serous ovarian/peritoneal cancer (LGSOC): Determinants of relapse and disease-free survival
- Current status and future perspectives in low-grade serous cancer of the ovary
- Does tumor grade infuence the rate of lymph node metastasis in apparent early stage ovarian cancer?
- Hormonal Maintenance Therapy for Women With Low-Grade Serous Cancer of the Ovary or Peritoneum
- Immunosuppressive microenvironment in low-grade serous ovarian carcinoma
- Low-Grade Serous Ovarian Cancer: Current Treatment Paradigms and Future Directions
- Low-grade serous ovarian cancer: State of the science
- Low grade serous ovarian cancer: Unpicking drivers of outcome
- Outcomes of Women With High-Grade and Low-Grade Advanced-Stage Serous Epithelial Ovarian Cancer
- Primary cytoreductive surgery and adjuvant hormonal monotherapy in women with advanced low-grade serous ovarian carcinoma: Reducing overtreatment without compromising survival?
- Recurrent low-grade serous ovarian carcinoma is relatively chemoresistant
- Should We Abandon Systematic Pelvic and Paraaortic Lymphadenectomy in Low-Grade Serous Ovarian Cancer?
- Survival and prognostic factors in patients with recurrent low-grade epithelial ovarian cancer: An analysis of five prospective phase II/III trials of NOGGO metadata base
- The role of neoadjuvant chemotherapy in the management of low-grade serous carcinoma of the ovary and peritoneum: Further evidence of relative chemoresistance
- The role of secondary cytoreduction in low-grade serous ovarian cancer or peritoneal cancer
- Trametinib versus standard of care in patients with recurrent low-grade serous ovarian cancer (GOG 281/LOGS): an international, randomised, open-label, multicentre, phase 2/3 trial
Reviews
- A systematic review and meta-analysis of hormone receptor expression in low-grade serous ovarian carcinoma
- Current status and future perspectives in low-grade serous cancer of the ovary
- Endocrine therapy in the management of low-grade serous ovarian/peritoneal carcinoma: Mounting evidence for therelative efficacy of tamoxifen and aromatase inhibitors
- Hormone maintenance therapy for women with low-grade serous ovarian cancer in the front-line setting: A systematic review
- low-grade epithelial ovarian cancer: what a radiologist should know
- Low-grade epithelial ovarian cancer: a number of distinct clinical entities?
- Low-grade serous epithelial ovarian cancer: a comprehensive review and update for radiologists
- Low-Grade Serous Ovarian Cancer: Current Treatment Paradigms and Future Directions
- Low Grade Serous Ovarian Carcinoma: From the molecular characterization to the best therapeutic strategy
- Low grade serous ovarian carcinoma: identifying variations in practice patterns
- Low grade serous ovarian cancer: Unpicking drivers of outcome
- Low-grade Serous Neoplasia of the Female Genital Tract
- Low-grade Serous Tumors: Are We Making Progress?
- Low-grade serous ovarian carcinoma: A comprehensive literature review
- Low-grade serous ovarian cancer: State of the science
- Management of low-grade, serous carcinomas of the ovary – UpToDate
- MEK Inhibitors for the Treatment of Low-Grade Serous Ovarian Cancer: Expanding Therapeutic Options for a Rare Ovarian Cancer Subtype
- Préservation de la fertilité, contraception et traitement hormonal de la ménopause chez les femmes traitées pour tumeurs malignes rares de l’ovaire : recommandations du réseau national dédié aux cancers gynécologiques rares (TMRG/GINECO)
- Targeting MAPK in recurrent, low-grade serous ovarian cancer
- Therapeutic Approach to Low-Grade Serous Ovarian Carcinoma: State of Art and Perspectives of Clinical Research
Clinical Research
Clinical Trials
- A pilot phase II study of neoadjuvant fulvestrant plus abemaciclib in women with advanced low-grade serous carcinoma
- EMR 20006-012: A phase II randomized double-blind placebo controlled trial comparing the combination of pimasertib (MEK inhibitor) with SAR245409 (PI3K inhibitor) to pimasertib alone in patients with previously treated unresectable borderline or low grade ovarian cancer
- MILO/ENGOT-ov11: Binimetinib Versus Physician’s Choice Chemotherapy in Recurrent or Persistent Low-Grade Serous Carcinomas of the Ovary, Fallopian Tube, or Primary Peritoneum
- PARAGON: A Phase II study of anastrozole in patients with estrogen receptor-positive recurrent/metastatic low-grade ovarian cancers and serous borderline ovarian tumors
- Phase I study of the combination of the dual RAF/MEK inhibitor VS-6766 and the FAK inhibitor defactinib: Results of efficacy in low grade serous ovarian cancer
- Phase II study of enzalutamide in androgen receptor positive, recurrent, high- and low-grade serous ovarian cancer
- Phase II trial of ribociclib and letrozole in patients with relapsed oestrogen receptor-positive ovarian or endometrial cancers
- Selumetinib in women with recurrent low-grade serous carcinoma of the ovary or peritoneum: an open-label, single-arm, phase 2 study
- Trametinib versus standard of care in patients with recurrent low-grade serous ovarian cancer (GOG 281/LOGS): an international, randomised, open-label, multicentre, phase 2/3 trial
Observational Research
- Activity of bevacizumab-containing regimens in recurrent low-grade serous ovarian or peritoneal cancer: A single institution experience
- Association between pelvic inflammatory disease, infertility, ectopic pregnancy and the development of ovarian serous borderline tumor, mucinous borderline tumor and low-grade serous carcinoma
- A survival analysis comparing women with ovarian low-grade serous carcinoma to those with high-grade histology
- Clinical factors associated with prognosis in low-grade serous ovarian carcinoma: experiences at two large academic institutions in Korea and Taiwan
- Contemporary primary treatment of women with stage II-IV low-grade serous ovarian/peritoneal cancer (LGSOC): Determinants of relapse and disease-free survival
- Cost-effectiveness of maintenance hormonal therapy in patients with advanced low grade serous ovarian cancer
- Diagnosis-shift between low-grade serous ovarian cancer and serous borderline ovarian tumor: A population-based study
- Disparities in care among patients with low-grade serous ovarian carcinoma
- Does lymph node ratio have any prognostic significance in maximally cytoreduced node‐positive low‐grade serous ovarian carcinoma?
- Does tumor grade infuence the rate of lymph node metastasis in apparent early stage ovarian cancer?
- Epidemiology of low-grade serous ovarian cancer
- Hormone receptor expression and outcomes in low-grade serous ovarian carcinoma
- Hormonal Maintenance Therapy for Women With Low-Grade Serous Cancer of the Ovary or Peritoneum
- Impact of cytoreductive surgery on survival of patients with low-grade serous ovarian carcinoma: A multicentric study of Turkish Society of Gynecologic Oncology (TRSGO-OvCa-001)
- Impact of lympho-vascular space invasion on tumor characteristics and survival outcome of women with low-grade serous ovarian carcinoma
- Increase in post-therapy tumor calcification on CT scan is not an indicator of response therapy in low-grade serous ovarian cancer
- Invasive Epithelial Ovarian Cancer Survival by Histotype and Disease Stage
- Ki67 expression as a predictor of chemotherapy outcome in low-grade serous ovarian cancer
- Low-grade serous carcinoma (LGSC): A Canadian multicenter review of practice patterns and patient outcomes
- Low-grade serous ovarian carcinoma: A retrospective study on 34 complete cytoreductive surgeries (in French)
- Low-grade serous ovarian carcinoma is a rare histological subtype in Japan
- Lymphovascular invasion as a criterion for adjuvant chemotherapy for FIGO stage I-IIa clear cell carcinoma, mucinous, low grade serous and low grade endometrioid ovarian cancer
- Lymphovascular space invasion and Ki67 as predictors of lymph node metastasis in primary low grade serous ovarian cancer
- MR imaging findings of low‐grade serous carcinoma of the ovary: comparison with serous borderline tumor
- Mutational spectrum in clinically aggressive low-grade serous carcinoma/serous borderline tumors of the ovary-Clinical significance of BRCA2 gene variants in genomically stable tumors
- Obesity Is Associated With Worse Overall Survival in Women With Low-Grade Papillary Serous Epithelial Ovarian Cancer
- Operability and chemotherapy responsiveness in advanced low-grade serous ovarian cancer. An analysis of the AGO Study Group metadatabase
- Outcomes of Women With High-Grade and Low-Grade Advanced-Stage Serous Epithelial Ovarian Cancer
- Patterns of Lymph Node Metastases in Apparent Stage I Low-Grade Epithelial Ovarian Cancer: A Multicenter Study
- Pregnancy and oncologic outcomes of early stage low grade epithelial ovarian cancer after fertility sparing surgery: a retrospective study in one tertiary hospital of China
- Primary cytoreductive surgery and adjuvant hormonal monotherapy in women with advanced low-grade serous ovarian carcinoma: Reducing overtreatment without compromising survival?
- Prognosis role of epitelial-mezenchimal transformation markers and surface stem tumor cells in the reccurence of serous low grade ovarian carcinomas
- Real-world outcomes in patients treated with trametinib for low grade serous ovarian carcinoma
- Recurrent low-grade serous ovarian carcinoma is relatively chemoresistant
- Should We Abandon Systematic Pelvic and Paraaortic Lymphadenectomy in Low-Grade Serous Ovarian Cancer?
- Survival and prognostic factors in patients with recurrent low-grade epithelial ovarian cancer: An analysis of five prospective phase II/III trials of NOGGO metadata base
- Stage II to IV Low-grade Serous Carcinoma of the Ovary Is Associated With a Poor Prognosis: A Clinicopathologic Study of 32 Patients From a Population-based Tumour Registry
- The clinical study of secondary cytoreductive surgery in the treatment of low grade serous ovarian cancer
- The detrimental effect of adopting interval debulking surgery in advanced stage low-grade serous ovarian cancer
- The Diagnostic Value of Serum CEA, CA-125, and ROMA Index in Low-Grade Serous Ovarian Cancer
- The Prognostic Relevance of the Proliferation Markers Ki-67 and Plk1 in Early-Stage Ovarian Cancer Patients With Serous, Low-Grade Carcinoma Based on mRNA and Protein Expression
- The role of neoadjuvant chemotherapy in the management of low-grade serous carcinoma of the ovary and peritoneum: Further evidence of relative chemoresistance
- The role of secondary cytoreduction in low-grade serous ovarian cancer or peritoneal cancer
- Trends of low-grade serous ovarian carcinoma in the United States
Case Studies
- Binimetinib (MEK162) in recurrent low-grade serous ovarian cancer resistant to chemotherapy and hormonal treatment
- Calcified Sister Mary Joseph nodule as the presenting complaint of advanced low-grade serous ovarian cancer
- Cardiophrenic lymph node metastasis in low-grade serous ovarian adenocarcinoma
- Complete response with combined BRAF and MEK inhibition in BRAF mutated advanced low-grade serous ovarian carcinoma
- Dramatic clinical response following dabrafenib and trametinib therapy in a T heavily pretreated low grade serous ovarian carcinoma patient with a BRAF V600E mutation
- Dramatic response to Laetrile and cannabidiol (CBD) oil in a patient with T metastatic low grade serous ovarian carcinoma
- Dual Fulvestrant-Trametinib Therapy in Recurrent Low-Grade Serous Ovarian Cancer
- Durable response to hormonal therapy in a patient with rapidly progressive low-grade serous ovarian cancer: A case report
- Fine needle aspiration cytology of a nodal low-grade serous neoplasm: a case report of low-grade serous carcinoma arising from a serous borderline tumour with cyto-histological correlation
- First evidence of a therapeutic effect of miransertib in a teenager with Proteus syndrome and ovarian carcinoma
- Ibrutinib Could Suppress CA-125 in Ovarian Cancer: A Hypothesis
- KRAS-Mutated, Estrogen Receptor-Positive Low-Grade Serous Ovarian Cancer: Unraveling an Exceptional Response Mystery
- Late recurrence of low-grade serous carcinoma of the ovary mimicking colorectal neoplasia
- Late recurrence of pStage 1 low-grade serous ovarian tumor presenting as a symptomatic bone metastasis: a case report
- Low-grade ovarian serous carcinoma metastasis to the maxilla
- Low-grade serous carcinoma (mullerian/ovarian type) of the paratestis presenting as diffuse metastatic disease of unknown origin: Case report of an uncommon tumor with an unusual presentation
- Low-grade serous carcinoma with extensive osseous metaplasia arising from ovarian serous cystadenofibroma
- Low-grade serous ovarian cancer in pregnancy
- Management of low-grade serous ovarian neoplasm in the setting of fertility preservation
- Mesonephric-Like Carcinosarcoma of the Ovary Associated with Low-Grade Serous Carcinoma: A Case Report
- Osseous Metaplasia in Low-grade Ovarian Serous Carcinoma With a BRAF Mutation: A Case Report
- Primary peritoneal low-grade serous carcinoma in a man: A case report and review of the literature
- Pulmonary tumour thrombotic microangiopathy as a cause of new-onset pulmonary hypertension in a patient with metastatic low-grade serous ovarian cancer
- Rare metastatic patterns after malignant transformation of serous borderline tumor of the ovary
- Recurrent low grade serous ovarian cancer in a 20 year old woman: A case from the Ohio State University College of Medicine
- Response to re-challenge of a MEK inhibitor in a patient with recurrent low-grade serous carcinoma of the peritoneum
- Response to trametinib in recurrent low-grade serous ovarian cancer with T NRAS mutation- A case report
- Targeted Next-Generation Sequencing Reveals Clinically Actionable BRAF and ESR1 Mutations in Low-Grade Serous Ovarian Carcinoma
- The poor prognosis of sarcomatoid carcinoma arising from low grade serous ovarian cancer: A case report and review of the literature
Pre-clinical Research
- An organoid platform for ovarian cancer captures intra- and interpatient heterogeneity
- A data science approach for the classification of low-grade and high-grade ovarian serous carcinomas
- An immunophenotyping of Ovarian Cancer with Clinical and Immunological Significance
- CAISMOV24, a new human low-grade serous ovarian carcinoma cell line
- Clinicopathologic and Molecular Features of Paired Cases of Metachronous Ovarian Serous Borderline Tumor and Subsequent Serous Carcinoma
- Clinicopathologic, Immunohistochemical, and Molecular Characteristics of Ovarian Serous Carcinoma With Mixed Morphologic Features of High-grade and Low-grade Serous Carcinoma
- Comprehensive in situ analysis of ALDH1 and SOX2 reveals increased expression of stem cell markers in high-grade serous carcinomas compared to low-grade serous carcinomas and atypical proliferative serous tumors
- Connective tissue growth factor mediates TGF-β1-induced low-grade serous ovarian tumor cell apoptosis
- Differences in MEK inhibitor efficacy in molecularly characterized low-grade serous ovarian cancer cell lines
- Differential cyclooxygenase expression levels and survival associations in type I and type II ovarian tumors
- Dishevelled family proteins in serous ovarian carcinomas: a clinicopathologic and molecular study
- EIF1AX and NRAS Mutations Co-occur and Cooperate in Low-Grade Serous Ovarian Carcinomas
- Establishment and characterization of a cell line and patient-derived xenograft (PDX) from peritoneal metastasis of low-grade serous ovarian carcinoma
- Extreme Outlier Analysis Identifies Occult Mitogen- Activated Protein Kinase Pathway Mutations in Patients With Low-Grade Serous Ovarian Cancer
- Gene expression profiles of ovarian low-grade serous carcinoma resemble those of fallopian tube epithelium
- Genomic analysis of low-grade serous ovarian carcinoma to identify key drivers and therapeutic vulnerabilities
- High Frequency of PIK3CA Mutations in Low-Grade Serous Ovarian Carcinomas of Japanese Patients
- Hormone receptor expression profile of low-grade serous ovarian cancers
- Identification of 12 new susceptibility loci for different histotypes of epithelial ovarian cancer
- Immunosuppressive microenvironment in low-grade serous ovarian carcinoma
- Inhibition of nuclear factor-kappa B enhances the tumor growth of ovarian cancer cell line derived from a low-grade papillary serous carcinoma in p53- independent pathway
- Interaction of ERα and NRF2 Impacts Survival in Ovarian Cancer Patients
- Intratumoral Heterogeneity Accounts for Apparent Progression of Noninvasive Serous Tumors to Invasive Low-grade Serous Carcinoma: A Study of 30 Low-grade Serous Tumors of the Ovary in 18 Patients With Peritoneal Carcinomatosis
- Lack of MRE11-RAD50-NBS1 (MRN) complex detection occurs frequently in low-grade epithelial ovarian cancer
- Loss of 1p36.33 Frequent in Low- Grade Serous Ovarian Cancer
- Low frequency of BRAF and KRAS mutations in Chinese patients with low-grade serous carcinoma of the ovary
- Low Grade Serous Ovarian Cancer: Is disturbed Receptor Ratio (ER: PgR) an Etiogenic Factor?
- Markers of MEK inhibitor resistance in low-grade serous ovarian cancer: EGFR is a potential therapeutic target
- Molecular alterations in indolent, aggressive and recurrent ovarian low-grade serous carcinoma
- mRNA expression in low grade serous ovarian cancer: Results of a nanoString assay in a diverse population
- Multiomics Characterization of Low-Grade Serous Ovarian Carcinoma Identifies Potential Biomarkers of MEK Inhibitor Sensitivity and Therapeutic Vulnerability
- MyD88 and TLR4 Expression in Epithelial Ovarian Cancer
- Mutation of NRAS is a rare genetic event in ovarian low-grade serous carcinoma
- Oncogenic BRAF and KRAS mutations in endosalpingiosis
- Ovarian Carcinoma Histotype: Strengths and Limitations of Integrating Morphology With Immunohistochemical Predictions
- Prognostic significance of Ki-67 levels and hormone receptor expression in low-grade serous ovarian carcinoma: an investigation of the tumor bank ovarian cancer network
- Proteome profiling of low grade serous ovarian cancer
- Proteomic Analysis of Low-Grade Serous Ovarian Cancer and Comparing It with Non-cancerous Ovarian
- Single-cell analysis of copy-number alterations in serous ovarian cancer reveals substantial heterogeneity in both low- and high-grade tumors
- STING pathway expression in low-grade serous carcinoma of the ovary: an unexpected therapeutic opportunity?
- Synergistic effect of MEK inhibitor and metformin combination in low grade serous ovarian cancer
- Tubal Origin of (Ovarian) Low-Grade Serous Carcinoma: A Gene Expression Profile Study
General research that may be of interest
- Approaches to Phase 1 Clinical Trial Design Focused on Safety, Efficiency and Selected Patient Populations: A Report from the Clinical Trial Design Task Force of the National Cancer Institute Investigational Drug Steering Committee
- Aromatase inhibitor use, side effects and discontinuation rates in gynecologic oncology patients
- A simple high-throughput approach identifies actionable drug sensitivities in patient-derived tumor organoids
- Assessing the risk of pelvic and para-aortic nodal involvement in apparent early-stage ovarian cancer: A predictors- and nomogram-based analyses
- Borderline Ovarian Tumours – UptoDate
- Circulating tumor cell-derived organoids: Current challenges and promises in medical research and precision medicine
- Covid-19 Outcomes of Patients with Gynaecological Cancer in New York City
- Do All Patients With Recurrent Ovarian Cancer Need Systemic Therapy?
- Doctor, Does This Mean I’m Going to Starve to Death?
- Double-blind, Randomized Trial of Alternative Letrozole Dosing Regimens in Postmenopausal Women with Increased Breast Cancer Risk
- Expression of L1 retrotransposon open reading frame protein 1 in gynecologic cancers
- Fasting, Starving Cancer (from The Lancet)
- Fertility-sparing Surgery for Patients with Cervical, Endometrial, and Ovarian Cancers
- Going to extremes: determinants of extraordinary response and survival in patients with cancer
- Immunohistochemistry: A diagnostic aid in differentiating primary epithelial ovarian tumors and tumors metastatic to the ovary
- Impact of young age on platinum response in women with epithelial ovarian cancer: Results of a large single-institution registry
- Inhibition of miR-214-3p Aids in Preventing Epithelial Ovarian Cancer Malignancy by Increasing the Expression of LHX6
- Intermittent schedules of the oral RAF-MEK inhibitor CH5126766/VS-6766 in patients with RAS/RAF-mutant solid tumours and multiple myeloma: a single-centre, open-label, phase 1 dose-escalation and basket dose-expansion study
- Mismatch Repair Deficiency in Ovarian Carcinoma: Frequency, Causes, and Consequences
- Nicotinamide N-methyltransferase overexpression may be associated with poor prognosis in ovarian cancer
- Not All Peritoneal Implants Are Created Equal
- Ovarian cancer in adolescents and young adults
- Pathology of borderline and invasive cancers
- Phytoestrogens in menopausal supplements induce ER-dependent cell proliferation and overcome breast cancer treatment in an in vitro breast cancer model
- Patient-derived organoids model treatment response of metastatic gastrointestinal cancers
- Patient-derived tumor organoids for prediction of cancer treatment response
- Prognostic indicators in ovarian serous borderline tumours
- Reduction/Prevention of Lower Extremity Lymphedema after Pelvic and Para-aortic Lymphadenectomy for Patients with Gynecologic Malignancies
- Serous ovarian tumors: Immunohistochemical profiling as an aid to grading and understanding tumorigenesis
- Soy isoflavones consumption and risk of breast cancer incidence or recurrence: a meta-analysis of prospective studies
- The Frequency and Prognostic Significance of the Histologic Type in Early-stage Ovarian Carcinoma
- The miR-34 family and its clinical significance in ovarian cancer
- Trends in incidence, treatment and survival of borderline ovarian tumors in the Netherlands: a nationwide analysis
- Whole solid tumour volume histogram analysis of the apparent diffusion coefficient for differentiating high-grade from low-grade serous ovarian carcinoma: correlation with Ki-67 proliferation status
Back to research and how to interpret it.